Skip to main content
Terug
APNHY logo

Aspen Pharmacare Holdings Limited

Datakwaliteit: 100%
APNHY
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 7,50
▼ € 0,40 (-5,06%)
Marktkapitalisatie: 3,33B
Ook genoteerd als APNHF OTC
Dagbereik
€ 7,50 € 8,86
52-Weeksbereik
€ 5,24 € 9,92
Volume
252
50D / 200D Gem.
€ 7,60 / € 6,43
Vorige Slotkoers
€ 7,90

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -3,1 0,4
P/B 0,0 2,9
ROE % -1,3 3,7
Net Margin % -2,5 3,8
Rev Growth 5Y % 3,5 10,0
D/E 0,4 0,2

Belangrijkste Punten

Revenue grew 3,52% annually over 5 years — modest growth
Earnings declined -124,59% over the past year
Debt/Equity of 0,43 — conservative balance sheet
Generating 104,00M in free cash flow
PEG of 0,40 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 6,52%

Groei

Revenue Growth (5Y)
3,52%
Revenue (1Y)-3,00%
Earnings (1Y)-124,59%
FCF Growth (3Y)-78,91%

Kwaliteit

Return on Equity
-1,28%
ROIC0,89%
Net Margin-2,50%
Op. Margin3,31%

Veiligheid

Debt / Equity
0,43
Current Ratio2,21
Interest Coverage0,87

Waardering

P/E Ratio
-3,07
P/B Ratio0,04
EV/EBITDA22,99
Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -3,00% Revenue Growth (3Y) 3,21%
Earnings Growth (1Y) -124,59% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 3,52% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 43,36B Net Income (TTM) -1,08B
ROE -1,28% ROA -0,80%
Gross Margin 44,11% Operating Margin 3,31%
Net Margin -2,50% Free Cash Flow (TTM) 104,00M
ROIC 0,89% FCF Growth (3Y) -78,91%
Safety
Debt / Equity 0,43 Current Ratio 2,21
Interest Coverage 0,87 Dividend Yield 0,03%
Valuation
P/E Ratio -3,07 P/B Ratio 0,04
P/S Ratio 0,08 PEG Ratio 0,40
EV/EBITDA 22,99 Dividend Yield 0,03%
Market Cap 3,33B Enterprise Value 33,04B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 43,36B 44,71B 40,71B 38,61B 37,77B
Net Income -1,08B 4,40B 5,23B 6,49B 4,81B
EPS (Diluted) -2,44 9,91 11,77 14,32 10,53
Gross Profit 19,13B 19,42B 18,41B 18,31B 17,79B
Operating Income 1,44B 7,00B 7,82B 8,67B 7,07B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 135,89B 139,16B 134,28B 111,38B 109,68B
Total Liabilities 51,00B 54,29B 48,05B 40,43B 44,06B
Shareholders' Equity 84,89B 84,86B 86,24B 70,94B 65,63B
Total Debt 36,12B 36,46B 29,28B 22,25B 24,87B
Cash & Equivalents 6,41B 12,34B 10,91B 6,18B 8,55B
Current Assets 38,70B 44,09B 44,50B 34,56B 32,71B
Current Liabilities 17,50B 24,38B 23,15B 23,40B 36,75B

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#772 of 820
13

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026